Nasus Pharma Ltd. (NSRX)
NYSE: NSRXHealthcareDrug Manufacturers - GeneralUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
NSRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $42.52M
- EPS (TTM)
- -$1.20
- Dividend yield
- None
- 52-week range
- 1.98 – 9.50
- Day range
- 3.50 – 3.69
- Volume / Avg
- 14.03K / 16.09K
- Beta
- —
- Shares outstanding
- 11.71M
52-week range
NSRX stock today
Shares of Nasus Pharma (NSRX) finished lower on Oct 8 at $3.63, a drop of 3.84% or $0.145 per share, versus the S&P 500's 0.47% decline. Shares are 61.8% below their 52-week high of $9.50, set on Dec 31, 2025 and 83.3% above the 52-week low of $1.98, in the middle of the past year's range. NSRX is down 60.3% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 50.1%.
Nasus Pharma has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Nasus Pharma
Company profileNasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Brendan P. O'Grady
- Headquarters
- Tel Aviv-Yafo
- Employees
- 7
- IPO year
- 2025
- Website
- nasuspharma.com
Analyst forecast
ForecastConsensus (2 analysts)
buy
Avg. price target
$19.67+441.87%
- Strong buy 2
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Nasus Pharma peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MIRAMIRA Pharmaceuticals Inc. | 0.703 | -0.99% | $29.54M | vs NSRX |
| SCLXScilex Holding Company | 2.96 | -15.19% | $20.82M | vs NSRX |
| MDCXMedicus Pharma Ltd. | 0.1019 | -36.39% | $7.31M | vs NSRX |
Indexes, lists and sector
Appears in lists
Nasus Pharma stock FAQ
What is Nasus Pharma's stock price today?
NSRX last traded at $3.63 as of Oct 8, 4:00 PM EDT, down 3.84% on the day. Prices are delayed at least 15 minutes.
Who is Nasus Pharma's CEO?
Mr. Brendan P. O'Grady is the chief executive officer of Nasus Pharma Ltd., which has about 7 employees.
What is the NSRX 52-week high?
The 52-week high for NSRX is $9.50 and the 52-week low is $1.98. The stock is currently 61.8% below its high.